Assembly Biosciences Doses First Two Participants in Phase 2 Trial of Hepatitis Delta Drug ABI-6250
Bitget2026/10/29 20:00- Assembly Biosciences dosed the first two participants in a Phase 2 trial of oral ABI-6250 for chronic hepatitis delta virus infection.
- The trial targets approximately 80 participants, testing two once-daily doses for safety and antiviral activity.
- Initial Phase 2 data are expected in the fourth quarter of 2027.
- Phase 1a results supported further development, with a mean half-life of approximately four days supporting once-daily dosing.
- Gilead holds an exclusive licensing option for ABI-6250 for $90 million through Phase 2 completion and review of the option data package.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bank of Japan minutes turn hawkish: Most members believe a rate hike is needed soon, with a 70% probability of a hike in December
Minutes from the Bank of Japan show that several members believe a rate hike is needed in the near term, with a roughly 70% probability of an increase in December. Core inflation has met the target for the first time in 30 years, and the current policy rate stands at 1.25%.
Former Chainlink Product Marketing Director Michael Robinson joins Monad Foundation
The Federal Reserve Eyes $1.8 Trillion in “Shadow Credit”: Dallas and New York Fed Launch First Private Credit Survey
The Dallas and New York Federal Reserves have launched an investigation into private credit lending standards, covering an industry worth 1.8 trillions USD, with a minimum threshold of 50 millions USD. The results will be released in the first quarter of 2027.
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Crypto prices
More
